GlassScriptPhysician profile
Humza Ilyas
NPI 1417120601
$3,007.24
in general payments reported to CMS, 2019-2025
27 companies · $692 in 2025
The $692 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $55.70 · 2021: $364 · 2022: $277 · 2023: $328 · 2024: $1,012 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.87 | 2019-2025 | |
| Leo Pharma INC. | $432.70 | 2023-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $186.02 | 2024-2025 | |
| Incyte Corporation | $174.49 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $162.67 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $135.55 | 2019-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $116.89 | 2021-2024 | Dupixent |
| Organogenesis INC. | $99.90 | 2019-2025 | Via Matrix, Cygnus Dual, Novachor |
| Dermavant Sciences, INC. | $98.51 | 2023-2024 | Vtama |
| Hydrofera LLC | $97.66 | 2024 | Hydrofera Blue |
| Sun Pharmaceutical Industries INC. | $94.13 | 2022-2025 | |
| Ucb, INC. | $73.47 | 2021-2024 | Bimzelx |
| Biofrontera INC. | $69.74 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $68.14 | 2023-2025 | |
| Amgen INC. | $65.79 | 2023-2025 | Otezla, Enbrel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.99 | 2019-2024 | Duobrii, Targretin, Siliq |
| Galderma Laboratories, L.P. | $50.59 | 2022-2025 | Aklief, Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.29 | 2024-2025 | Spevigo |
| Pfizer INC. | $36.73 | 2021-2022 | |
| Genzyme Corporation | $32.79 | 2023 | |
| Verrica Pharmaceuticals INC. | $21.11 | 2024 | Ycanth |
| Dusa Pharmaceuticals, INC. | $20.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.95 | 2021 | |
| Lnhc, INC | $18.55 | 2025 | Zelsuvmi |
| Genentech USA, INC. | $16.89 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.69 | 2025 | Valchlor |
| Teva Pharmaceuticals USA, INC. | $14.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humza Ilyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.